MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors.
GI cancers
drug resistance
microRNAs
targeted therapy
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
21 Mar 2021
21 Mar 2021
Historique:
received:
07
02
2021
revised:
17
03
2021
accepted:
18
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
The advent of precision therapies against specific gene alterations characterizing different neoplasms is revolutionizing the oncology field, opening novel treatment scenarios. However, the onset of resistance mechanisms put in place by the tumor is increasingly emerging, making the use of these drugs ineffective over time. Therefore, the search for indicators that can monitor the development of resistance mechanisms and above all ways to overcome it, is increasingly important. In this scenario, microRNAs are ideal candidate biomarkers, being crucial post-transcriptional regulators of gene expression with a well-known role in mediating mechanisms of drug resistance. Moreover, as microRNAs are stable molecules, easily detectable in tissues and biofluids, they are the ideal candidate biomarker to identify patients with primary resistance to a specific targeted therapy and those who have developed acquired resistance. The aim of this review is to summarize the major studies that have investigated the role of microRNAs as mediators of resistance to targeted therapies currently in use in gastro-intestinal neoplasms, namely anti-EGFR, anti-HER2 and anti-VEGF antibodies, small-molecule tyrosine kinase inhibitors and immune checkpoint inhibitors. For every microRNA and microRNA signature analyzed, the putative mechanisms underlying drug resistance were outlined and the potential to be translated in clinical practice was evaluated.
Identifiants
pubmed: 33801049
pii: biomedicines9030318
doi: 10.3390/biomedicines9030318
pmc: PMC8003870
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Italian Health Ministry
ID : NET-2016-02363853
Références
Hepatology. 2013 Aug;58(2):629-41
pubmed: 23471579
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
PLoS One. 2014 Oct 15;9(10):e109430
pubmed: 25329796
Cancers (Basel). 2019 Jun 24;11(6):
pubmed: 31238586
Exp Ther Med. 2017 Jul;14(1):657-663
pubmed: 28672982
Nat Med. 2017 Nov;23(11):1331-1341
pubmed: 29035371
Cancer Sci. 2019 Feb;110(2):662-673
pubmed: 30485589
Mol Clin Oncol. 2014 Mar;2(2):175-181
pubmed: 24649329
Neoplasma. 2018 Sep 19;65(5):683-692
pubmed: 30249101
Biomed Pharmacother. 2017 Sep;93:1065-1073
pubmed: 28738500
J Clin Oncol. 2016 Feb 10;34(5):443-51
pubmed: 26628478
PLoS One. 2014 Dec 22;9(12):e115565
pubmed: 25531114
Oncotarget. 2015 Jul 30;6(21):18389-405
pubmed: 26158762
Semin Oncol. 2015 Dec;42(6):896-908
pubmed: 26615134
Drugs. 2015 Aug;75(12):1435-45
pubmed: 26220913
Expert Opin Ther Targets. 2012 Jan;16(1):15-31
pubmed: 22239438
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Adv Anat Pathol. 2015 May;22(3):194-201
pubmed: 25844677
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
Cell. 2013 Apr 25;153(3):516-9
pubmed: 23622238
Oncotarget. 2015 Nov 17;6(36):38695-704
pubmed: 26497852
Oncogene. 2007 May 28;26(25):3637-43
pubmed: 17530017
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
Lancet Oncol. 2019 Mar;20(3):420-435
pubmed: 30718072
Mol Cancer Res. 2019 Jun;17(6):1403-1413
pubmed: 30872332
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
J Clin Oncol. 2007 Apr 20;25(12):1539-44
pubmed: 17442997
Oncologist. 2012;17(6):823-9
pubmed: 22584434
Front Oncol. 2019 Sep 20;9:849
pubmed: 31616627
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Nat Rev Cancer. 2006 May;6(5):369-81
pubmed: 16633365
Clin Colorectal Cancer. 2014 Mar;13(1):37-45.e4
pubmed: 24503111
Oncotarget. 2016 Jul 19;7(29):45370-45384
pubmed: 27248318
BMC Cancer. 2019 Nov 21;19(1):1130
pubmed: 31752758
Int J Mol Sci. 2020 Oct 03;21(19):
pubmed: 33023006
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
Int J Mol Med. 2018 Aug;42(2):998-1007
pubmed: 29786108
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
Cells. 2020 Jan 07;9(1):
pubmed: 31936122
Curr Drug Targets. 2018;19(14):1721-1729
pubmed: 29484992
Cell. 2005 Mar 11;120(5):635-47
pubmed: 15766527
Clin Cancer Res. 2007 Mar 1;13(5):1552-61
pubmed: 17332301
Oncogene. 2011 Aug 11;30(32):3489-501
pubmed: 21383697
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Gastroenterology. 2019 May;156(6):1731-1741
pubmed: 30738047
Hum Pathol. 2015 May;46(5):665-72
pubmed: 25800719
Leukemia. 2019 Jan;33(1):132-147
pubmed: 29946193
Cancer Gene Ther. 2018 May;25(3-4):68-76
pubmed: 29302045
Proc Natl Acad Sci U S A. 1986 Jun;83(11):3825-9
pubmed: 2424012
Gastric Cancer. 2015 Oct;18(4):729-39
pubmed: 25240408
Cancer Discov. 2014 Nov;4(11):1269-80
pubmed: 25293556
Cancer Lett. 2014 Oct 1;352(2):245-52
pubmed: 25034398
Br J Cancer. 2014 Nov 25;111(11):2091-102
pubmed: 25349971
Mol Cancer. 2013 Dec 13;12:162
pubmed: 24330766
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
Technol Cancer Res Treat. 2014 Feb;13(1):77-86
pubmed: 23862748
Cancer Lett. 2017 Jul 1;397:111-119
pubmed: 28365400
JAMA Oncol. 2018 Aug 1;4(8):1093-1098
pubmed: 29710180
Sci Rep. 2016 Oct 12;6:35316
pubmed: 27731397
Ann Surg Oncol. 2015 Aug;22(8):2640-8
pubmed: 25472647
J Clin Pathol. 2014 Mar;67(3):198-203
pubmed: 24098024
Mol Oncol. 2017 Jul;11(7):878-891
pubmed: 28544151
Int J Mol Sci. 2014 Aug 08;15(8):13768-801
pubmed: 25110867
PLoS One. 2015 Jul 27;10(7):e0133754
pubmed: 26214687
Hepatol Res. 2015 Dec;45(13):1312-22
pubmed: 25655186
Ann Oncol. 2001;12 Suppl 1:S3-8
pubmed: 11521719
Dev Cell. 2008 Aug;15(2):261-71
pubmed: 18694565
Acta Biochim Biophys Sin (Shanghai). 2014 Jan;46(1):72-5
pubmed: 24217767
Hum Mutat. 2012 Mar;33(3):480-4
pubmed: 22190470
Pharmacogenomics J. 2019 Oct;19(5):455-464
pubmed: 30686821
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
J Hepatol. 2010 May;52(5):698-704
pubmed: 20347499
Transl Res. 2019 Mar;205:77-91
pubmed: 30391474
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Clin Cancer Res. 2014 Jun 15;20(12):3338-47
pubmed: 24771647
Oncotarget. 2016 May 31;7(22):32925-32
pubmed: 27147580
Oncotarget. 2018 Nov 23;9(92):36411-36412
pubmed: 30559926
Gastric Cancer. 2015 Jul;18(3):476-84
pubmed: 25038874
Clin Exp Med. 2015 May;15(2):137-44
pubmed: 24706111
Adv Cancer Res. 2017;135:1-24
pubmed: 28882219
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Clin Cancer Res. 2005 Jun 1;11(11):4182-90
pubmed: 15930355
Ann Surg Oncol. 2014 Jan;21(1):343-50
pubmed: 24154840
Clin Cancer Res. 2017 Jul 15;23(14):3953-3965
pubmed: 28096271
Oncotarget. 2015 Feb 20;6(5):3211-24
pubmed: 25633810
Cell Death Dis. 2018 Jan 5;9(1):4
pubmed: 29305580
J Exp Clin Cancer Res. 2018 Jul 13;37(1):151
pubmed: 30005681
Oncotarget. 2015 Oct 6;6(30):28867-81
pubmed: 26311740
JAMA Oncol. 2018 Apr 1;4(4):529-536
pubmed: 29450468
Am Soc Clin Oncol Educ Book. 2020 May;40:161-173
pubmed: 32421451
Clin Cancer Res. 2010 Feb 1;16(3):957-66
pubmed: 20103677
Mod Pathol. 2012 May;25(5):637-50
pubmed: 22222640
Expert Opin Ther Targets. 2015;19(8):1017-26
pubmed: 26107137
Mod Pathol. 2019 Feb;32(2):306-313
pubmed: 30206410
Cells. 2020 Jan 23;9(2):
pubmed: 31979244
N Engl J Med. 2004 Jul 22;351(4):337-45
pubmed: 15269313
PLoS One. 2014 Jun 18;9(6):e99886
pubmed: 24940606
Lab Invest. 2016 Jun;96(6):652-60
pubmed: 26950487
Cancer Cell. 2004 Aug;6(2):117-27
pubmed: 15324695
Lancet Oncol. 2013 Jan;14(1):29-37
pubmed: 23168366
Int J Mol Sci. 2018 Jan 20;19(1):
pubmed: 29361687
Oncogene. 2016 Dec 1;35(48):6189-6202
pubmed: 27157613
Theranostics. 2019 Oct 22;9(26):8409-8425
pubmed: 31754405
Cancer Cell. 2007 Sep;12(3):192-9
pubmed: 17785201
Curr Opin Genet Dev. 2013 Feb;23(1):12-9
pubmed: 23453900
J Biol Chem. 2009 Nov 13;284(46):32015-27
pubmed: 19726678
Methods Mol Biol. 2016;1395:137-62
pubmed: 26910073
N Engl J Med. 2002 Aug 15;347(7):472-80
pubmed: 12181401
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Microvasc Res. 2017 Nov;114:26-33
pubmed: 28595801
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Int J Cancer. 2015 Apr 1;136(7):1537-45
pubmed: 25159729
Signal Transduct Target Ther. 2020 Jun 10;5(1):87
pubmed: 32532960
Int J Biochem Cell Biol. 2020 Jan;118:105643
pubmed: 31704502
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Front Oncol. 2018 Jun 18;8:226
pubmed: 29967761
Cancer Treat Rev. 2020 Aug;88:102030
pubmed: 32505807
J Clin Med. 2019 Dec 02;8(12):
pubmed: 31810268
Curr Opin Pharmacol. 2020 Oct;54:44-50
pubmed: 32898724
Oncotarget. 2017 Jan 17;8(3):3980-4000
pubmed: 28002810